Watson Institute for International and Public Affairs
Facebook Twitter YouTube Trending Globally Podcast Instagram LinkedIn Tumblr Email list

The Dark Arts

September 16, 2016 The Economist

John Friedman comments on the benefits that drugmakers have seen since the revision of the Medicare program in 2003. "This included a new prescription-drug benefit but no measures to control the costs of that benefit through means-testing or bulk-buying. John Friedman, an economist at Brown University, estimated the resulting benefits to drugmakers at $242 billion over ten years, a healthy return on the $130m the industry spent on lobbying in the year the law was passed."

The Dark Arts (comments by John Friedman) – The Economist